Vendis Capital has sealed a €290m sale of Belgian teeth, mouth and skincare products business Sylphar to EQT portfolio business Karo Pharma.
The private equity house bought Sylphar in 2017 from Concordia. The company was formed in 2007 by company CEO Robin List, who remains an investor.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Sylphar’s brands include Nutravita, Alpha Foods, Remescar and iWhite.
Vendis said that since its investment Sylphar had expanded its digital presence, its category of products and its geographic footprint.
Bolt-on acquisitions included Nutravita in 2018 and Alpha Foods in 2020.
EQT bought Sweden’s Karo Pharma two years ago in a $694m deal. The business develops and markets products for pharmacies and other areas of the healthcare sector.
Source: Alt Assets
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...